Abbreviated Name

PaCa Pre-Dx Bake Off 3 Set Aside

Lead Investigator

— University of Pittsburgh

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Lokshin, Anna — University of Pittsburgh Cancer Institute
• — Stanford University
• Batra, Surinder — University of Nebraska Medical Center
• Lampe, Paul — Fred Hutchinson Cancer Center
• Haab, Brian — Van Andel Research Institute
• — University of Pittsburgh
• Hanash, Samir — The University of Texas MD Anderson Cancer Center
• Maitra, Anirban — The University of Texas M D Anderson Cancer Center
• Srivastava, Sudhir — National Cancer Institute
• Li, Debiao — Cedars Sinai
• Von Hoff, Daniel — Translational Genomics Research Institute
• Rosenthal, Michael — Dana Farber Cancer Institute
• Goel, Ajay — City of Hope
• Majumder, Shounak — Mayo Clinic
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

No abstract availalbe.

Aims

Aim 1. Assemble and distribute samples from pre-diagnostic cohorts Aim 2. Test the individual and combination markers that were suggested by the previous team projects in pre-diagnostic cohorts

Analytic Method

Dr. Huang at the FHCRC will perform the statistical analyses. The goal will be to determine performance of each biomarker or biomarker panel and whether each panel passes the minimumperformance requirement. Receiver operating characteristic curve will be estimated for each individual marker and CA199, with 95% confidence interval for each point on the ROC curve estimated using 1000 bootstrap resamples. If the lower bound of the 95% confidence interval of the tested biomarker exceeds the minimum performance criterion (40% sensitivity at 95% specificity), the biomarker will have passed the performance criterion. For comparison with CA19-9, the panel will have passed the performance criterion if the lower bound of 95% confidence interval of the difference in performance between the panel and CA19-9 exceeds zero. For biomarkers not meeting the target performance, we will perform secondary analyses to determine the cause of the failure and strategies for further development (see alternative strategies). Biomarker panels cross labs will also be developed using various algorithms, including logistic regression (for its simplicity and oftentimes relatively robust performance in classification), classification tree, and support vector machine. Best panel will be selected based on cross-validated performance. Panels will be developed for specimens collected within different periods prior to disease diagnosis (<1yr, <2yr, <3yr, <4yr, <5yr).

Publications

• No publications available at this time for this protocol.

Biomarkers

• ANGPTL3
• ANGPTL4
• APOA1
• bHCG
• CA125
• CA19-9
• CEACAM1
• CEACAM5
• CRP
• CTSD
• ENO2
• IGFBP1
• IGFBP3
• LRG1
• MUC4
• MUC5AC
• Osteopontin
• PRL
• SAA@
• sTRA
• THSP
• TIMP1
• TIMP3
• TNFRSF11B
• VCAM1

Data Collections

• No data collections available at this time for this protocol.

 Team Project

Protocol ID

467

Protocol Type

Collaboration

Fields of Research

• Glycomics
• Proteomics

Collaborative Group

G.I. and Other Associated Cancers Research Group

Cancer Types

• Malignant neoplasm of pancreas

Phased Status

1